Description: Recap of the Brazil Insurance Markets in 2008.

Description: Q&A with President Life & Health US. Swiss Re. Neil Sprackling.

Description: In session 76 PD of the Maui II Spring Meeting the panel discusses the exodus of many carriers from marketing both life and health products in favor of life, AD&D, and LTC products. From the Record of the Society of Actuaries, Vol. 24, No. 1.

Description: In this webcast, presenters will outline the key content in ERM ASOPs 46, 47 and 55 and explore the impact each ASOP has on practitioners working in these fields. We will also describe the revision work currently under way in the ERM Committee of the Actuarial Standards Board.

Description: Presented at May 1996 Spring Meeting. Traditional reinsurers have become more conservative in recent years as the individual disability insurance industry continues to report poor financial results. Some reinsurers have exited the marketplace, while some others have raised rates, restricted certain coverages, tightened underwriting, and taken other actions to manage the risks. Thus, alternatives to traditional DI reinsurance are discussed.

Description: With the IDI market consolidating, panelists at this session 47PD of the Palm Desert Spring Meeting discuss significant considerations in selling or buying a block of IDI business, relative to reinsurance, valuation, tax, and regulatory issues. From the Record of the Society of Actuaries, Vol. 23, No. 1.

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: A glossary of terms.

Description: This webcast will walk through several statistical methods for imputing race and ethnicity from U.S. datasets, highlighting strengths and weaknesses and evaluating accuracy.

Description: As more gene and cell therapies enter the market at increasingly higher price points, they are ushering in a new era of medicine for rare diseases. Unlike most traditional therapies, gene and cell therapies typically have a short or one-time treatment administration and are anticipated to provide long-term clinical benefits. Actuaries must be prepared to assess, manage, and/or mitigate the risks associated with these therapies. This session includes three different perspectives—a regional plan, a stop loss/reinsurance carrier, and a health care consultant.